Literature DB >> 1676038

Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

L J Levitt1, A Nagler, F Lee, J Abrams, M Shatsky, D Thompson.   

Abstract

Resting natural killer (NK) cells express the p75 chain of the IL-2 receptor (IL-2R beta) and most NK cells express the CD2 (erythrocyte rosette) receptor. The cell adhesion molecule, LFA-3, is a natural co-ligand for CD2. Tac antigen (IL-2R alpha), a p55 IL-2R subunit, can be expressed after NK activation and may play a role in IL-2-induced NK proliferation. Little is known of the molecular mechanisms underlying cytokine production in NK cells. We investigated the roles of IL-2R alpha, IL-2R beta, and CD2/LFA-3 in the molecular regulation of NK cell granulocyte/macrophage-colony-stimulating factor (GM-CSF) production. Enriched populations of peripheral blood NK cells were separated into CD16-positive and CD16-negative fractions by flow cytometry; positively selected cells were greater than 97% positive for CD16 (the FcIII receptor for IgG which is present on almost all NK cells), less than 1% positive for the T cell antigen CD3, and did not demonstrate rearrangement of the T cell receptor beta chain gene by Southern blot. NK cell supernatants were harvested after 3-4 d of incubation with 0-100 U/ml IL-2, or after incubation with anti-CD2 (T11(3] MAb and sheep red blood cells (SRBC are a homologue for LFA-3). Parallel cell aliquots were harvested at 3-16 h for transcriptional run-on assays, S1 nuclease assays, and actinomycin D mRNA t1/2 determinations. IL-2-activated NK supernatants contained large amounts of GM-CSF (178 +/- 35 pg/ml) by ELISA as did supernatants from CD2-activated NK cells (T11(3) MAb + SRBC: 212 +/- 42) vs. less than 20 pg/ml for NK cells incubated alone or with either SRBC or T11(3) MAb alone. Sepharose-linked anti-CD3 MAb did not induce GM-CSF release from NK cells. By S1 analysis, both IL-2 and CD2 stimulation markedly augmented GM-CSF mRNA expression but with very different latencies of onset. IL-2R beta MAb inhibited greater than 85% of GM-CSF release from IL-2-activated NK cells and markedly suppressed IL-2-induced GM-CSF mRNA expression, whereas IL-2R alpha MAb even at 2,000-fold molar excess of IL-2 had little effect (less than 10%) on either GM-CSF release or mRNA expression. Run-on assays showed that GM-CSF is constitutively transcribed in NK cells and that IL-2 and CD2-activated cells had a three- to fourfold increased rate of GM-CSF transcription compared to nonstimulated cells. The t1/2 of GM-CSF mRNA in IL-2-activated NK cells was identical to that of unstimulated NK cells (15 min), whereas GM-CSF mRNA t1/2 in CD2-activated NK cells was increased 2.5-fold. We conclude that GM-CSF production in NK cells is regulated by both the IL-2Rbeta and the CD2 receptor but not by IL-2Ralpha, that both transcriptional and posttranscriptional signals act together to modulate the level of GM-CSF mRNA in NK cells, and that the molecular mechanisms underlying NK cell GM-CSF production are dependent in part on differential surface receptor activation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676038      PMCID: PMC296004          DOI: 10.1172/JCI115306

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Cloning of a cDNA for a T cell-specific serine protease from a cytotoxic T lymphocyte.

Authors:  H K Gershenfeld; I L Weissman
Journal:  Science       Date:  1986-05-16       Impact factor: 47.728

2.  In vivo function of natural killer cells as regulators of myeloid precursor cells in the spleen.

Authors:  M Hansson; M Petersson; G C Koo; H Wigzell; R Kiessling
Journal:  Eur J Immunol       Date:  1988-03       Impact factor: 5.532

Review 3.  The human interleukin-2 receptor: a molecular and biochemical analysis of structure and function.

Authors:  W C Greene
Journal:  Clin Res       Date:  1987-09

4.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

5.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.

Authors:  R J Robb; W C Greene; C M Rusk
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

6.  Human T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease.

Authors:  L J Levitt; G R Reyes; D K Moonka; K Bensch; R A Miller; E G Engleman
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

7.  Monoclonal antibody defining a molecule possibly identical to the p75 subunit of interleukin 2 receptor.

Authors:  T Takeshita; Y Goto; K Tada; K Nagata; H Asao; K Sugamura
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

8.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

9.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

10.  Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen.

Authors:  L L Lanier; D W Buck; L Rhodes; A Ding; E Evans; C Barney; J H Phillips
Journal:  J Exp Med       Date:  1988-05-01       Impact factor: 14.307

View more
  10 in total

1.  Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

Authors:  O Asai; D L Longo; Z G Tian; R L Hornung; D D Taub; F W Ruscetti; W J Murphy
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

2.  Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Authors:  T Hoeres; M Wilhelm; M Smetak; E Holzmann; G Schulze-Tanzil; J Birkmann
Journal:  Clin Exp Immunol       Date:  2018-01-04       Impact factor: 4.330

3.  Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.

Authors:  Nelli Bejanyan; Claudio G Brunstein; Qing Cao; Aleksandr Lazaryan; Xianghua Luo; Julie Curtsinger; Rohtesh S Mehta; Erica Warlick; Sarah A Cooley; Bruce R Blazar; Jeffrey S Miller; Daniel Weisdorf; John E Wagner; Michael R Verneris
Journal:  Blood Adv       Date:  2018-04-24

4.  HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells.

Authors:  Fatiha Tabet; Kasey C Vickers; Luisa F Cuesta Torres; Carrie B Wiese; Bassem M Shoucri; Gilles Lambert; Claire Catherinet; Leonel Prado-Lourenco; Michael G Levin; Seth Thacker; Praveen Sethupathy; Philip J Barter; Alan T Remaley; Kerry-Anne Rye
Journal:  Nat Commun       Date:  2014-02-28       Impact factor: 14.919

5.  Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment.

Authors:  Maite Alvarez; Kai Sun; William J Murphy
Journal:  Blood       Date:  2016-01-06       Impact factor: 22.113

6.  Regulated production of a pleiotropic cytokine-platelet-derived growth factor--by differentiating erythroid cells in vitro and in vivo.

Authors:  J C Keutzer; A J Sytkowski
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  Interleukin-21 differentially affects human natural killer cell subsets.

Authors:  Katy Wendt; Esther Wilk; Sabine Buyny; Reinhold Ernst Schmidt; Roland Jacobs
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

Review 8.  Therapeutic use of Aldara in chronic myeloid leukemia.

Authors:  Annette M Marleau; Jeffrey H Lipton; Neil H Riordan; Thomas E Ichim
Journal:  J Transl Med       Date:  2007-01-25       Impact factor: 5.531

9.  PyNTTTTGT and CpG immunostimulatory oligonucleotides: effect on granulocyte/monocyte colony-stimulating factor (GM-CSF) secretion by human CD56+ (NK and NKT) cells.

Authors:  Juan M Rodriguez; José Marchicio; Mariela López; Andrea Ziblat; Fernanda Elias; Juan Fló; Ricardo A López; David Horn; Jorge Zorzopulos; Alejandro D Montaner
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

10.  Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets.

Authors:  Michelle L Robinette; Anja Fuchs; Victor S Cortez; Jacob S Lee; Yaming Wang; Scott K Durum; Susan Gilfillan; Marco Colonna
Journal:  Nat Immunol       Date:  2015-01-26       Impact factor: 25.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.